- Home
- DVAX vs INMD Comparison
DVAX vs INMD Comparison
Compare DVAX & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- INMD
- Stock Information
- Founded
- DVAX 1996
- INMD 2008
- Country
- DVAX United States
- INMD Israel
- Employees
- DVAX N/A
- INMD N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- INMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DVAX Health Care
- INMD Health Care
- Exchange
- DVAX Nasdaq
- INMD Nasdaq
- Market Cap
- DVAX 1.2B
- INMD 964.9M
- IPO Year
- DVAX 2004
- INMD 2019
- Fundamental
- Price
- DVAX $11.21
- INMD $14.01
- Analyst Decision
- DVAX Buy
- INMD Hold
- Analyst Count
- DVAX 4
- INMD 6
- Target Price
- DVAX $26.50
- INMD $17.00
- AVG Volume (30 Days)
- DVAX 1.7M
- INMD 588.8K
- Earning Date
- DVAX 11-05-2025
- INMD 11-05-2025
- Dividend Yield
- DVAX N/A
- INMD N/A
- EPS Growth
- DVAX N/A
- INMD 20.42
- EPS
- DVAX N/A
- INMD 2.21
- Revenue
- DVAX $330,514,000.00
- INMD $364,494,000.00
- Revenue This Year
- DVAX $23.23
- INMD N/A
- Revenue Next Year
- DVAX $16.57
- INMD $5.02
- P/E Ratio
- DVAX N/A
- INMD $6.41
- Revenue Growth
- DVAX 26.73
- INMD N/A
- 52 Week Low
- DVAX $9.20
- INMD $13.14
- 52 Week High
- DVAX $14.63
- INMD $19.83
- Technical
- Relative Strength Index (RSI)
- DVAX 64.07
- INMD 34.19
- Support Level
- DVAX $10.97
- INMD $14.08
- Resistance Level
- DVAX $11.43
- INMD $14.79
- Average True Range (ATR)
- DVAX 0.36
- INMD 0.32
- MACD
- DVAX 0.07
- INMD -0.08
- Stochastic Oscillator
- DVAX 86.42
- INMD 6.34
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.